Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: LeMaitre Vascular is a global provider of medical devices and implants for the treatment of peripheral vascular disease. The company operates in a single reportable segment, developing, manufacturing, and marketing vascular devices used in open surgery and endovascular procedures. Key products include the Expandable LeMaitre Valvulotome, Pruitt F3 Carotid Shunt, and VascuTape Radiopaque Tape. The company employs a direct sales force of 67 representatives in North America, the European Union, and Japan, generating approximately 93% of net sales through this channel.
Key Financial Metrics
| Metric | 2010 | 2009 | Change |
|---|---|---|---|
| Net Sales | $56.1 million | $50.9 million | +10% |
| Gross Profit | $41.7 million | $37.3 million | +12% |
| Gross Margin | 74.4% | 73.3% | +1.1% |
| Operating Income | $4.0 million | $1.9 million | +106% |
| Net Income | $6.0 million | $1.6 million | +276% |
| Diluted EPS | $0.37 | $0.10 | +270% |
| Cash and Cash Equivalents | $22.6 million | $23.2 million | -3% |
| Total Assets | $63.3 million | $56.9 million | +11% |
| Total Liabilities | $10.9 million | $8.7 million | +25% |
Debt and Liquidity: The company terminated its $10 million revolving line of credit in August 2010 and had no borrowings outstanding as of year-end. Cash provided by operating activities was $7.1 million in 2010. The company maintains a strong liquidity position with no long-term debt.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% to $56.1 million, driven primarily by a 17% increase in the Vascular product category (valvulotomes, biologic patches, carotid shunts) and higher average selling prices. This was partially offset by a 3% decline in the Endovascular category due to reduced sales of TAArget and UniFit stent grafts.
- Profitability Surge: Net income increased significantly to $6.0 million, largely due to a $2.0 million tax benefit resulting from the release of a $3.3 million valuation allowance on U.S. deferred tax assets after achieving three years of cumulative profitability.
- Restructuring Charges: The company incurred $1.8 million in restructuring charges in 2010, primarily related to the closure of its Biomateriali manufacturing facility in Brindisi, Italy, and the transition of production to Burlington, Massachusetts. This included $1.4 million in severance costs.
- Acquisitions and Divestitures: In November 2010, the company acquired the LifeSpan ePTFE Vascular Graft for $2.8 million. Conversely, it discontinued R&D and suspended clinical studies for its TAArget and UniFit aortic stent grafts in October 2010, initiating a process to divest these products.
- Foreign Currency Impact: Foreign currency fluctuations negatively impacted sales by approximately $0.9 million (2% of growth) due to the strengthening of the U.S. dollar against the euro.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- Direct Sales Expansion: The company plans to convert distribution models to direct sales in Spain and Denmark in 2011, which is expected to increase sales and marketing expenses temporarily.
- Manufacturing Transition: The relocation of AlboGraft manufacturing from Italy to the U.S. is expected to continue impacting gross margins in 2011 due to start-up costs.
- Dividend Policy: In February 2011, the Board approved a quarterly cash dividend of $0.02 per share, with the first payment scheduled for April 2011.
- Share Repurchase: The company has an authorized repurchase program of up to $5.0 million, with approximately $2.2 million remaining available as of December 31, 2010.
Risks and Contingencies:
- Product Liability and Recalls: The company withdrew the UnBalloon Non-Occlusive Modeling Catheter in 2010 due to design issues. Future recalls or liability claims could harm reputation and financial results.
- Regulatory and Reimbursement: The company faces risks related to FDA approvals, particularly for PMA-required devices (which it has paused for stent grafts), and potential reductions in third-party reimbursement rates due to healthcare reform (PPACA).
- Supply Chain: Reliance on single-source suppliers for key components and third-party manufacturers for certain products (e.g., EndoRE) poses supply disruption risks.
- Intellectual Property: The company relies on patents and licenses; infringement claims or the loss of licensing rights (e.g., for stent grafts) could materially impact operations.
Investor Verification Checklist
- Tax Benefit Sustainability: Verify the assumptions regarding the release of the $3.3 million valuation allowance and the utilization of U.S. net operating loss carryforwards, as this significantly boosted 2010 net income.
- Stent Graft Divestiture: Monitor the progress of the divestiture process for the TAArget and UniFit stent grafts, as the company has ceased development and expects sales to decline further.
- Manufacturing Transition Costs: Track the actual costs and timeline for relocating AlboGraft production from Italy to Massachusetts, as this impacts future gross margins.
- Direct Sales Conversion: Assess the financial impact of transitioning Spain and Denmark from distributor to direct sales models in 2011, including potential short-term revenue dips and increased operating expenses.
- Foreign Currency Exposure: Evaluate the company's hedging strategy (or lack thereof) given that 38% of sales are international and subject to exchange rate volatility.